GolimuRel (Golimumab) is a fully human IgG1κ monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-α, which prevents the binding of TNF-α to its receptors. The protein has an approximate molecular weight of 150 KDa and exhibits multiple glycoforms. GolimuRel (Golimumab) is produced by a recombinant cell line process.

GolimuRel (Golimumab) is indicated currently in combination with methotrexate for the treatment of adult patients with moderately to severely active Rheumatoid Arthritis. It is also indicated for patients with active Ankylosing Spondylitis.